What Are The New Treatments For Hairy Cell Leukemia?

Hairy cell leukemia is a rare, slow-growing cancer of the blood and bone marrow. For most people diagnosed with it, the standard first treatment is a purine analog drug called cladribine, and it works very well. The newest developments are not a single new drug that replaces everything — they are better ways to use existing drugs, targeted therapies for people whose cancer comes back, and a clearer understanding of who can safely wait before starting treatment at all.

What Is Hairy Cell Leukemia?

Hairy cell leukemia (HCL) is a cancer of B lymphocytes, a type of white blood cell that normally helps fight infection. In HCL, the bone marrow makes too many abnormal B cells. Under a microscope these cells have fine, hair-like projections, which is where the name comes from.

It is uncommon. HCL accounts for roughly 2 percent of all adult leukemias. It is diagnosed most often in middle-aged and older adults, and men are affected about four times as often as women.

The abnormal cells build up in the bone marrow and crowd out normal blood cell production. That leads to low counts of red blood cells (anemia), low platelets (which can cause easy bruising or bleeding), and low normal white blood cells (which raises infection risk). The spleen often enlarges. Fatigue is the most common symptom.

One detail that matters: HCL usually grows slowly. Many people have no symptoms at diagnosis, and the disease is often found by accident on a routine blood test.

What Are The New Treatments For Hairy Cell Leukemia?

The biggest shift in HCL treatment is not a new drug for everyone. It is matching treatment to the situation. There are three main areas of change.

First, more people are being watched instead of treated right away. Because HCL is slow-growing, people with mild blood count changes and no symptoms may not need treatment at diagnosis. This is called active surveillance. Several studies have found that many people can safely go years without treatment. This is a real change from the past, when almost everyone was treated soon after diagnosis.

Second, the standard drugs are being used more thoughtfully. Cladribine and pentostatin are purine analogs — drugs that damage DNA in dividing cells. Cladribine can be given as a short infusion or as a series of injections under the skin. These drugs remain the backbone of first treatment and produce long-lasting remissions in most people.

Third, targeted drugs are now available for people whose cancer comes back or does not respond. These include BRAF inhibitors and drugs that block B-cell receptor signaling. This is where most of the genuine “new” treatment activity is happening.

It is worth being clear about what has not changed. No new drug has replaced cladribine as first-line treatment for typical HCL. The new options are mostly for relapsed or hard-to-treat disease.

How Do BRAF Inhibitors Fit In?

About 80 to 90 percent of classic HCL cases carry a specific mutation in a gene called BRAF, known as BRAF V600E. That mutation drives the cancer cells to grow. This discovery opened the door to using BRAF inhibitor drugs, which are already used in melanoma.

Vemurafenib and dabrafenib are the two BRAF inhibitors studied in HCL. They are not usually used as first treatment. They are used mainly when the disease has come back after purine analog treatment, or when someone cannot tolerate those drugs.

The evidence here is real but limited. Small studies and case series have shown that BRAF inhibitors can produce strong responses in relapsed HCL. But these are not large randomized trials, and the responses are often not permanent when the drug is used alone. Some clinicians combine a BRAF inhibitor with rituximab, an antibody that targets B cells, to get deeper and longer responses.

One practical point: BRAF inhibitors can cause skin problems, including a risk of skin cancer, and can cause fever and joint pain. People taking them need monitoring. This is a real trade-off, not a minor detail.

What About Rituximab and Other Options?

Rituximab is a monoclonal antibody that attaches to a protein called CD20 on B cells. HCL cells carry CD20, so rituximab can help clear them.

Rituximab is rarely used alone for HCL. It is most often used in combination — with a purine analog, with a BRAF inhibitor, or in people who cannot have standard treatment. It tends to work best when the number of cancer cells in the blood is low.

Another targeted approach blocks B-cell receptor signaling. Ibrutinib and moxetumomab pasudotox are two examples that have been studied in relapsed or refractory HCL.

• Ibrutinib blocks an enzyme called BTK that B cells rely on. It has shown activity in some people with relapsed HCL, including some with the BRAF mutation and some without it.
• Moxetumomab pasudotox is a different kind of drug. It is an antibody attached to a toxin. The antibody targets CD22 on HCL cells and delivers the toxin directly to them. It was approved for relapsed or refractory HCL, though it is not widely used and can cause a serious side effect called capillary leak syndrome, which needs careful monitoring.

These are specialist options. They are not first-line treatments, and they are not right for everyone. The choice depends on prior treatments, the specific features of the cancer, and the person’s overall health.

Why Is Treatment for Hairy Cell Leukemia Different From Other Leukemias?

HCL behaves differently from most leukemias, and that changes how it is treated.

Many leukemias need treatment right away. HCL often does not. It can stay stable for years. Because of that, watching and waiting is a legitimate option, not a delay of necessary care.

HCL also responds unusually well to purine analogs. A single course of cladribine can keep the disease under control for many years in a large share of people. That is not typical for most cancers.

There is a catch, though. HCL is not cured in the sense that the cancer cells are completely gone. Even after treatment, small numbers of cancer cells often remain. This is called minimal residual disease. Over time, the disease can come back. Doctors monitor blood counts regularly to catch this.

Some people also have a variant form of HCL that does not carry the BRAF mutation and does not respond as well to standard treatment. This variant is harder to treat and needs a different approach.

Are There Newer Drugs Still Being Studied?

Yes, but the honest picture is that most are early-stage.

Researchers are testing combinations — for example, a BRAF inhibitor plus rituximab, or a purine analog plus rituximab — to see if they produce deeper and longer responses than single drugs. Some of these combinations have shown promising results in small studies.

Newer BTK inhibitors and other signaling drugs are also being looked at for relapsed disease. So are antibody-drug conjugates, which are antibodies carrying a toxic payload directly to cancer cells.

A caution here: many of these are in early trials with small numbers of people. Promising early results do not always hold up in larger studies. No one should assume a drug in a phase 1 or phase 2 trial is better than standard treatment.

What Should You Ask Your Doctor?

Because HCL is rare, it is usually treated by a hematologist, often one with experience in blood cancers. If you or someone you know has been diagnosed, these questions can help guide the conversation.

• Do I need treatment now, or can we watch and wait?
• What are the expected benefits and risks of cladribine for me?
• If the disease comes back, what options would we consider?
• Should I be tested for the BRAF mutation?
• Would a clinical trial be a good fit?
• How often will my blood counts be checked?

There is no single right answer for everyone. The best plan depends on symptoms, blood counts, prior treatment, and overall health.